FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904340483> ?p ?o ?g. }

• W2904340483 endingPage "128" @default.
• W2904340483 startingPage "118" @default.
• W2904340483 abstract "Study Objective Ustekinumab was recently approved by the United States U.S. Food and Drug Administration for the treatment of Crohn's disease. In this analysis, we aimed to compare the cost-effectiveness of ustekinumab, infliximab, or adalimumab for the treatment of moderate-severe Crohn's disease in patients who failed conventional therapy (i.e., corticosteroids and immunomodulators) but were naïve to tumor necrosis factor antagonists (i.e., biologic drugs). Design Cost-effectiveness analysis using a hybrid model structure (decision tree and Markov model). Measurements and Main Results A decision tree simulated biologic induction, and a Markov model simulated biologic and conventional therapy maintenance. Cycle length was 2 weeks with a discounted 5-year time horizon and a limited U.S. societal perspective in the base case; results from a payer perspective are also reported. Transition probabilities, direct costs, indirect costs, and utilities were obtained from the literature. To measure relative treatment value (i.e., order of treatment cost-effectiveness), net monetary benefits were reported for a $150,000 willingness-to-pay threshold per quality-adjusted life-year in the base case. Infliximab dominated both adalimumab and ustekinumab, with a net monetary benefit (NMB) of $9943 and $29,798, respectively, in the base case. Adalimumab dominated ustekinumab, with an NMB of $19,855. All biologics yielded similar quality-adjusted life-years (~3.5), whereas costs varied substantially ($50,510, $54,985, and $72,921 for infliximab, adalimumab, and ustekinumab, respectively). The payer perspective, alternate time horizons, and scenario analyses consistently showed infliximab dominance. One-way, threshold, and probabilistic sensitivity analyses confirmed the robustness of these results with respect to all parameters. Although biosimilars were not explicitly modeled as comparators, one-way sensitivity analysis showed that drug acquisition costs could alter relative treatment value but would have to be varied by at least 50%. Conclusion For moderate-severe Crohn's disease, infliximab yields significantly more NMBs compared with both adalimumab and ustekinumab. Additional clinical (e.g., empiric dosing, biologic cycling) and quality-of-life (e.g., lost productivity, disutility of home injections) research is needed to allow for model frameworks and parameters that more accurately reflect the nuances of Crohn's disease treatment." @default.
• W2904340483 created "2018-12-22" @default.
• W2904340483 creator A5009160605 @default.
• W2904340483 creator A5043977478 @default.
• W2904340483 creator A5080378534 @default.
• W2904340483 date "2019-01-20" @default.
• W2904340483 modified "2023-10-17" @default.
• W2904340483 title "Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients" @default.
• W2904340483 cites W1593673554 @default.
• W2904340483 cites W1932836507 @default.
• W2904340483 cites W1991810959 @default.
• W2904340483 cites W1991890714 @default.
• W2904340483 cites W2012440800 @default.
• W2904340483 cites W2014298657 @default.
• W2904340483 cites W2025792594 @default.
• W2904340483 cites W2028738437 @default.
• W2904340483 cites W2064225893 @default.
• W2904340483 cites W2086636575 @default.
• W2904340483 cites W2106160422 @default.
• W2904340483 cites W2111570058 @default.
• W2904340483 cites W2112635226 @default.
• W2904340483 cites W2118422544 @default.
• W2904340483 cites W2142082253 @default.
• W2904340483 cites W2144550346 @default.
• W2904340483 cites W2152026434 @default.
• W2904340483 cites W2169467558 @default.
• W2904340483 cites W2171341132 @default.
• W2904340483 cites W2321453230 @default.
• W2904340483 cites W2405717207 @default.
• W2904340483 cites W2559983657 @default.
• W2904340483 cites W2620203957 @default.
• W2904340483 cites W3149527659 @default.
• W2904340483 cites W4233817719 @default.
• W2904340483 doi "https://doi.org/10.1002/phar.2208" @default.
• W2904340483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30565265" @default.
• W2904340483 hasPublicationYear "2019" @default.
• W2904340483 type Work @default.
• W2904340483 sameAs 2904340483 @default.
• W2904340483 citedByCount "9" @default.
• W2904340483 countsByYear W29043404832019 @default.
• W2904340483 countsByYear W29043404832020 @default.
• W2904340483 countsByYear W29043404832021 @default.
• W2904340483 countsByYear W29043404832022 @default.
• W2904340483 countsByYear W29043404832023 @default.
• W2904340483 crossrefType "journal-article" @default.
• W2904340483 hasAuthorship W2904340483A5009160605 @default.
• W2904340483 hasAuthorship W2904340483A5043977478 @default.
• W2904340483 hasAuthorship W2904340483A5080378534 @default.
• W2904340483 hasConcept C112930515 @default.
• W2904340483 hasConcept C126322002 @default.
• W2904340483 hasConcept C2777138892 @default.
• W2904340483 hasConcept C2778975655 @default.
• W2904340483 hasConcept C2779134260 @default.
• W2904340483 hasConcept C2779280984 @default.
• W2904340483 hasConcept C2780132546 @default.
• W2904340483 hasConcept C3019080777 @default.
• W2904340483 hasConcept C64332521 @default.
• W2904340483 hasConcept C71924100 @default.
• W2904340483 hasConceptScore W2904340483C112930515 @default.
• W2904340483 hasConceptScore W2904340483C126322002 @default.
• W2904340483 hasConceptScore W2904340483C2777138892 @default.
• W2904340483 hasConceptScore W2904340483C2778975655 @default.
• W2904340483 hasConceptScore W2904340483C2779134260 @default.
• W2904340483 hasConceptScore W2904340483C2779280984 @default.
• W2904340483 hasConceptScore W2904340483C2780132546 @default.
• W2904340483 hasConceptScore W2904340483C3019080777 @default.
• W2904340483 hasConceptScore W2904340483C64332521 @default.
• W2904340483 hasConceptScore W2904340483C71924100 @default.
• W2904340483 hasIssue "2" @default.
• W2904340483 hasLocation W29043404831 @default.
• W2904340483 hasLocation W29043404832 @default.
• W2904340483 hasOpenAccess W2904340483 @default.
• W2904340483 hasPrimaryLocation W29043404831 @default.
• W2904340483 hasRelatedWork W2799849060 @default.
• W2904340483 hasRelatedWork W2804271470 @default.
• W2904340483 hasRelatedWork W2895221936 @default.
• W2904340483 hasRelatedWork W2902953632 @default.
• W2904340483 hasRelatedWork W2960758672 @default.
• W2904340483 hasRelatedWork W2984488335 @default.
• W2904340483 hasRelatedWork W3000137031 @default.
• W2904340483 hasRelatedWork W3207621403 @default.
• W2904340483 hasRelatedWork W4200518998 @default.
• W2904340483 hasRelatedWork W4255520715 @default.
• W2904340483 hasVolume "39" @default.
• W2904340483 isParatext "false" @default.
• W2904340483 isRetracted "false" @default.
• W2904340483 magId "2904340483" @default.
• W2904340483 workType "article" @default.